Perfromance Wealth Partners LLC Reduces Holdings in Eli Lilly and Company $LLY

Perfromance Wealth Partners LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 12.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 29,705 shares of the company’s stock after selling 4,262 shares during the period. Eli Lilly and Company accounts for about 0.7% of Perfromance Wealth Partners LLC’s portfolio, making the stock its 18th largest position. Perfromance Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $23,156,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LLY. Hobbs Wealth Management LLC raised its stake in Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock valued at $1,205,000 after purchasing an additional 12 shares during the last quarter. Hixon Zuercher LLC grew its holdings in shares of Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock worth $1,477,000 after buying an additional 12 shares in the last quarter. O Brien Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after buying an additional 12 shares during the last quarter. Ascent Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 2.5% during the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock valued at $409,000 after buying an additional 12 shares during the period. Finally, Tennessee Valley Asset Management Partners lifted its stake in shares of Eli Lilly and Company by 2.7% during the first quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company’s stock valued at $407,000 after buying an additional 13 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity

In other Eli Lilly and Company news, CEO David A. Ricks acquired 1,632 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock worth $2,894,841. Insiders own 0.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on LLY. Guggenheim lifted their target price on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Finally, Cantor Fitzgerald set a $925.00 price target on Eli Lilly and Company and gave the company an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $948.06.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $818.60 on Tuesday. The business’s fifty day moving average price is $743.43 and its 200 day moving average price is $765.54. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $774.77 billion, a P/E ratio of 53.50, a PEG ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.